Skip to main content

Table 4 Univariable and multivariable Cox proportional hazard analyses of prognostic factors for disease-specific survival of patients with PDAC

From: High expression of p62/SQSTM1 predicts shorter survival for patients with pancreatic cancer

Variable

Univariable analysis

Multivariable analysisa

HR

95% CI

p

HR

95% CI

p

Age

 < 65 years

1

  

1

  

 ≥65 years

1.59

0.65–3.89

0.312

1.40

0.39–5.09

0.608

Sex

 Female

1

  

1

  

 Male

0.76

0.33–1.77

0.525

0.59

0.19–1.86

0.366

Tumor location

 Head

1

     

 Others

1.46

0.32–6.55

0.624

 

N.A.

 

Tumor stage

 pT1–2

1

  

1

  

 pT3–4

1.26

0.55–2.92

0.587

1.15

0.30–4.37

0.839

Differentiation

 Medium or high

1

  

1

  

 Low

1.19

0.45–3.13

0.728

1.05

0.27–4.09

0.942

Lymph node metastasis

 N0

1

  

1

  

 N1

1.09

0.45–2.62

0.847

0.90

0.31–2.61

0.841

Adjuvant chemotherapy

 No

1

  

1

  

 Yes

0.42

0.15–1.18

0.101

0.37

0.10–1.34

0.130

p62

 Low

1

  

1

  

 High

2.88

1.17–7.11

0.022

3.83

1.24–11.84

0.020

LC3

 Low

1

     

 High

0.64

0.25–1.63

0.349

 

N.A.

 

NRF2

 Low

1

     

 High

1.02

0.43–2.45

0.957

 

N.A.

 
  1. aModel including p62, age, sex, tumor stage, differentiation, lymph node metastasis, and adjuvant therapy. HR Hazard ratio, CI Confidence interval, low Staining grade low, high Staining grade high, pT Pathologic evaluation of tumor specimen, N0/N1 No presence/presence of regional lymph node metastasis, N.A. Not analyzed. Adjuvant chemotherapy = postoperative gemcitabine treatment